BioCentury | Apr 20, 2020
Product Development

Opdivo-Cabometyx combo improves PFS by 49%, OS by 40% in first-line RCC

Exelixis jumped $4.14 (21%) to $23.58 on Monday, pushing its valuation above $7 billion, after the biotech and partners Bristol Myers Squibb and Ipsen said the combination of Opdivo nivolumab plus Cabometyx cabozantinib generated positive...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular...
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

Revolution’s first day performance suggests appetite for new biotech listings continues unabated in 2020, as investors’ demand for the cancer company’s shares rose both before and after its offering priced. Revolution Medicines Inc. (NASDAQ:RVMD) raised...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BC Extra | Nov 22, 2019
Clinical News

Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

Tecentriq continues to carve out a niche in the crowded PD-1/PD-L1 space as new survival data for the drug in the combination with Avastin in hepatocellular carcinoma pave the way for the regimen to become...
BC Extra | Oct 1, 2019
Financial News

Three new IPO filings broaden fall queue

A trio of biotechs filed for NASDAQ listings late Monday, with Phathom, 4D Molecular Therapeutics and Cabaletta each proposing to raise up to $100 million. A fourth, Vir, set terms for an IPO that could...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
BioCentury | Sep 14, 2019
Finance

Mark Schoenebaum: Setting the gold standard

In a business dominated by numbers, calculations, dollars and cents, Mark Schoenebaum understood that humanity, kindness and humility are paramount. This understanding gave him a boost that allowed him to reinvent what it means to...
BC Extra | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

Although more than half of the $630.7 million in equity funding that Vir Biotechnology has raised remains unspent, the immunology and infectious disease company -- led by former Biogen and Exelixis CEO George Scangos --...
BC Extra | Jul 31, 2019
Company News

July 31 Company Quick Takes: Bayer, Orion win approval in prostate cancer; plus Keytruda, Roche-Spark, UC v. Broad and more

Bayer, Orion androgen receptor inhibitor approved for prostate cancer  FDA approved an NDA for Nubeqa darolutamide from Bayer AG (Xetra:BAYN) and Orion Corp. (HSE:ORNAV; HSE:ORNBV) to treat non-metastatic castration-resistant prostate cancer. The oral androgen receptor...
Items per page:
1 - 10 of 960
BioCentury | Apr 20, 2020
Product Development

Opdivo-Cabometyx combo improves PFS by 49%, OS by 40% in first-line RCC

Exelixis jumped $4.14 (21%) to $23.58 on Monday, pushing its valuation above $7 billion, after the biotech and partners Bristol Myers Squibb and Ipsen said the combination of Opdivo nivolumab plus Cabometyx cabozantinib generated positive...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular...
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

Revolution’s first day performance suggests appetite for new biotech listings continues unabated in 2020, as investors’ demand for the cancer company’s shares rose both before and after its offering priced. Revolution Medicines Inc. (NASDAQ:RVMD) raised...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BC Extra | Nov 22, 2019
Clinical News

Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

Tecentriq continues to carve out a niche in the crowded PD-1/PD-L1 space as new survival data for the drug in the combination with Avastin in hepatocellular carcinoma pave the way for the regimen to become...
BC Extra | Oct 1, 2019
Financial News

Three new IPO filings broaden fall queue

A trio of biotechs filed for NASDAQ listings late Monday, with Phathom, 4D Molecular Therapeutics and Cabaletta each proposing to raise up to $100 million. A fourth, Vir, set terms for an IPO that could...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
BioCentury | Sep 14, 2019
Finance

Mark Schoenebaum: Setting the gold standard

In a business dominated by numbers, calculations, dollars and cents, Mark Schoenebaum understood that humanity, kindness and humility are paramount. This understanding gave him a boost that allowed him to reinvent what it means to...
BC Extra | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

Although more than half of the $630.7 million in equity funding that Vir Biotechnology has raised remains unspent, the immunology and infectious disease company -- led by former Biogen and Exelixis CEO George Scangos --...
BC Extra | Jul 31, 2019
Company News

July 31 Company Quick Takes: Bayer, Orion win approval in prostate cancer; plus Keytruda, Roche-Spark, UC v. Broad and more

Bayer, Orion androgen receptor inhibitor approved for prostate cancer  FDA approved an NDA for Nubeqa darolutamide from Bayer AG (Xetra:BAYN) and Orion Corp. (HSE:ORNAV; HSE:ORNBV) to treat non-metastatic castration-resistant prostate cancer. The oral androgen receptor...
Items per page:
1 - 10 of 960